Dr. Reddy’s laboratory. File |Picture Credit score: The Hindu
Dr. Reddy’s Laboratories introduced on Thursday (July 9, 2026) that it’s suspending business provides of generic semaglutide as a consequence of points associated to the lively pharmaceutical ingredient (API) used within the drug, and that new shipments will seemingly resume in late October or early November.
The choice despatched shares of the Hyderabad-based drug firm down practically 6 per cent after BSE and Torrent Prescription drugs introduced a voluntary recall of some Semarix injection disposable pens manufactured on Dr. Reddy’s directions.
“Sure batches of semaglutide had been discovered to be substandard as a consequence of points associated to the API used within the product. Industrial provide of the product will likely be delayed for a time frame till the difficulty is resolved,” Dr. Reddy’s mentioned in a submitting.
The corporate mentioned there is no such thing as a affect on affected person security or the product’s present world regulatory filings.
Semaglutide is the lively ingredient in Novo Nordisk’s blockbuster diabetes and weight reduction medication Wigovy and Ozempic. Dr. Reddy’s is among the many Indian drug corporations that rolled out generic variations of semaglutide shortly after its patent expired in March.
Chief Government Officer Erez Israel mentioned in a night name with analysts that the choice to halt business provides was made after an unknown impurity was found throughout a manufacturing scale-up. An intensive investigation will likely be performed to establish the foundation trigger and needed course of enhancements will likely be made. Industrial provide will resume solely after the revised manufacturing course of has been absolutely validated, which is able to inevitably affect availability for purchasers in India and Canada.
He sought to make clear that there aren’t any affected person security implications related to the merchandise already obtainable available on the market. A substandard product was found throughout scale-up and was not shipped. There’s additionally no affect on the provision of semaglutide oral tablets, which make the most of completely different API sources, he mentioned.
With business provide unlikely to final greater than three months, it’s unlikely that Dr. Reddy’s will attain its 12 million pen objective this 12 months. He mentioned 6 million to 7 million pens might be offered within the third to fourth quarters of 2027. The corporate’s shares closed 5.85 per cent decrease at Rs 1,269.80 on the BSE.
Individually, Torrent Prescription drugs introduced that it has issued a voluntary recall of solely a choose batch of Semarix injection disposable pens as a precautionary measure. “This motion follows a product recall discover issued by our producer, Dr. Reddy’s Laboratories, for technical analysis,” the corporate mentioned.
Mr. Israel mentioned the recall associated to some batches in India and had nothing to do with “the problems we’re discussing.”
